

of the Sequence Listing, file "0020-4954P.ST25", is identical to the paper copy, except that it lacks formatting.

The amendments made to the specification are intended to reference each nucleotide sequence by a unique SEQ ID NO. No new matter is introduced by this amendment.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By *Raymond C. Stewart Jr. #28977*  
Raymond C. Stewart, #21,066

*for*  
P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

*pw*  
RCS/PW/BCF  
0020-4954P

Attachments: Disk Copy of Sequence Listing  
Paper Copy of Sequence Listing  
Copy of Notice

(Rev. 03/27/01)

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

The paragraph beginning on page 24, line 10:

-- Primer sequences(forward and reverse), and the length of the amplified products were as follows (SEQ ID NOS: 1-26): --

The paragraph beginning on page 33, line 17:

-- By means of RT-PCR described in Example 1, the nerve like cells was confirmed to express Nurt-1 transcription factor. The primer sequences used herein for detecting Nurt-1 were as follows:

TGAAGAGAGC GGAGAAGGAG ATC (SEQ ID NO: 27)

TCTGGAGTTA AGAAATCGGA GCTG (SEQ ID NO: 28)

255 bp. --